Optimising treatment for Australian melanoma patients can save taxpayers millions of dollars annually

Medical Journal of Australia

Volumn 202, Issue 3, 2015, Pages 1-

  Gedye, Craig ^a,b   Boyle, Frances M ^c  

^a CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^c Mater Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DABRAFENIB; IPILIMUMAB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; OXIME;

ADAPTIVE IMMUNITY; ECONOMIC ASPECT; GENE MUTATION; HEALTH CARE; HUMAN; LETTER; MELANOMA; OVERALL SURVIVAL; ANTAGONISTS AND INHIBITORS; AUSTRALIA; COST CONTROL; DRUG COST; ECONOMICS; HEALTH CARE COST; IMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUSTRALIA; COST SAVINGS; DRUG COSTS; HEALTH CARE COSTS; HUMANS; IMIDAZOLES; IMMUNOTHERAPY; MELANOMA; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84928243858     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja14.01202     Document Type: Letter

References (6)

1. 1 Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-1703.
2. 2 Ascierto PA, Simeone E, Sileni VC, et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest 2014; 32: 144-149.
3. 3 Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014; 120: 1695-1701.
4. 4 Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-1246.
5. Australian Institute of Health and Welfare, Australasian Association of Cancer Registries. Cancer in Australia: an overview, 2012. Canberra: AIHW, 2012: 116. (AIHW Cat. No. CAN 70; Cancer Series No. 74.)
6. 6 Menzies AM, Haydu LE, Visintin L, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18: 3242-3249.